

Robert T Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3877404/publications.pdf>

Version: 2024-02-01

59
papers

4,568
citations

186265

28
h-index

138484

58
g-index

62
all docs

62
docs citations

62
times ranked

3878
citing authors

#	ARTICLE	IF	CITATIONS
1	A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus. <i>Vaccine</i> , 2022, 40, 5263-5274.	3.8	2
2	Advancing the Science of Vaccine Safety During the Coronavirus Disease 2019 (COVID-19) Pandemic and Beyond: Launching an International Network of Special Immunization Services. <i>Clinical Infectious Diseases</i> , 2022, 75, S11-S17.	5.8	8
3	A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273). <i>Vaccine</i> , 2022, 40, 5275-5293.	3.8	3
4	Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment. <i>Vaccine</i> , 2022, 40, 5248-5262.	3.8	9
5	How to ensure we can track and trace global use of COVID-19 vaccines?. <i>Vaccine</i> , 2021, 39, 176-179.	3.8	8
6	Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment. <i>Vaccine</i> , 2021, 39, 3081-3101.	3.8	51
7	The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform. <i>Vaccine</i> , 2021, 39, 3067-3080.	3.8	36
8	Suitability of databases in the Asia-Pacific for collaborative monitoring of vaccine safety. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 843-857.	1.9	5
9	The Brighton Collaboration standardized templates for collection of key information for benefit-risk assessment of vaccines by technology (BRAVATO; formerly V3SWG). <i>Vaccine</i> , 2021, 39, 3050-3052.	3.8	3
10	Evolving pharmacovigilance requirements with novel vaccines and vaccine components. <i>BMJ Global Health</i> , 2021, 6, e003403.	4.7	6
11	The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines. <i>Vaccine</i> , 2020, 38, 6184-6189.	3.8	6
12	The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines. <i>Vaccine</i> , 2020, 38, 5734-5739.	3.8	6
13	Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines. <i>Vaccine</i> , 2020, 38, 7702-7707.	3.8	6
14	The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines. <i>Vaccine</i> , 2020, 38, 5556-5561.	3.8	9
15	Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. <i>Vaccine</i> , 2020, 38, 4783-4791.	3.8	102
16	The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines. <i>Vaccine</i> , 2020, 38, 7708-7715.	3.8	4
17	Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines. <i>Vaccine</i> , 2019, 37, 5796-5802.	3.8	18
18	Hospital-based collaboration for epidemiological investigation of vaccine safety: A potential solution for low and middle-income countries?. <i>Vaccine</i> , 2018, 36, 345-346.	3.8	2

#	ARTICLE	IF	CITATIONS
19	Vaccination and unexplained sudden death risk in Taiwanese infants. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 17-25.	1.9	12
20	Laboratory-based performance evaluation of PIMA CD4 + T-lymphocyte count point-of-care by lay-counselors in Kenya. <i>Journal of Immunological Methods</i> , 2017, 448, 44-50.	1.4	11
21	Effect of point-of-care CD4 cell count results on linkage to care and antiretroviral initiation during a home-based HIV testing campaign: a non-blinded, cluster-randomised trial. <i>Lancet HIV</i> , 2017, 4, e393-e401.	4.7	19
22	Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment. <i>Vaccine</i> , 2016, 34, 6597-6609.	3.8	53
23	Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains. <i>Vaccine</i> , 2016, 34, 6610-6616.	3.8	32
24	Adventitious agents and live viral vectored vaccines: Considerations for archiving samples of biological materials for retrospective analysis. <i>Vaccine</i> , 2016, 34, 6617-6625.	3.8	21
25	Enhancing Vaccine Safety Capacity Globally. <i>American Journal of Preventive Medicine</i> , 2015, 49, S364-S376.	3.0	6
26	Enhancing vaccine safety capacity globally: A lifecycle perspective. <i>Vaccine</i> , 2015, 33, D46-D54.	3.8	41
27	Live virus vaccines based on a yellow fever vaccine backbone: Standardized template with key considerations for a risk/benefit assessment. <i>Vaccine</i> , 2015, 33, 62-72.	3.8	56
28	The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). <i>Vaccine</i> , 2015, 33, 73-75.	3.8	26
29	Template protocol for clinical trials investigating vaccines—Focus on safety elements. <i>Vaccine</i> , 2013, 31, 5602-5620.	3.8	17
30	Roadmap for the international collaborative epidemiologic monitoring of safety and effectiveness of new high priority vaccines. <i>Vaccine</i> , 2013, 31, 3623-3627.	3.8	25
31	Investigation of an outbreak of hypersensitivity-type reactions during the 2004 national measles-mumps-rubella vaccination campaign in Brazil. <i>Vaccine</i> , 2013, 31, 950-954.	3.8	16
32	Preparing for the availability of a partially effective HIV vaccine: Some lessons from other licensed vaccines. <i>Vaccine</i> , 2011, 29, 6072-6078.	3.8	7
33	Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies. <i>Vaccine</i> , 2009, 27, 2282-2288.	3.8	48
34	A Process for Sentinel Case Review to Assess Causal Relationships between Smallpox Vaccination and Adverse Outcomes, 2003–2004. <i>Clinical Infectious Diseases</i> , 2008, 46, S271-S293.	5.8	11
35	Active Surveillance of Vaccine Safety. <i>Epidemiology</i> , 2005, 16, 336-341.	2.7	137
36	Use of the Inactivated Intranasal Influenza Vaccine and the Risk of Bell's Palsy in Switzerland. <i>New England Journal of Medicine</i> , 2004, 350, 896-903.	27.0	810

#	ARTICLE	IF	CITATIONS
37	Evaluation of vaccine safety after the events of 11 September 2001: role of cohort and case-control studies. <i>Vaccine</i> , 2004, 22, 2047-2053.	3.8	21
38	Standardized case definitions of adverse events following immunization (AEFI). <i>Vaccine</i> , 2004, 22, 547-550.	3.8	38
39	Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. <i>Pediatric Infectious Disease Journal</i> , 2004, 23, 287-294.	2.0	323
40	The Brighton Collaboration: enhancing comparability of vaccine safety data. <i>Pharmacoepidemiology and Drug Safety</i> , 2003, 12, 335-340.	1.9	50
41	Myocarditis: the unexpected return of smallpox vaccine adverse events. <i>Lancet, The</i> , 2003, 362, 1345-1346.	13.7	32
42	Vaccinations and Risk of Central Nervous System Demyelinating Diseases in Adults. <i>Archives of Neurology</i> , 2003, 60, 504.	4.5	233
43	Vaccine safety surveillance using large linked databases: opportunities, hazards and proposed guidelines. <i>Expert Review of Vaccines</i> , 2003, 2, 21-29.	4.4	38
44	Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001. <i>MMWR Surveillance Summaries</i> , 2003, 52, 1-24.	34.6	90
45	The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). <i>Vaccine</i> , 2002, 21, 298-302.	3.8	134
46	Prevalence of Anti-Gelatin IgE Antibodies in People With Anaphylaxis After Measles-Mumps-Rubella Vaccine in the United States. <i>Pediatrics</i> , 2002, 110, e71-e71.	2.1	108
47	Epidemiology of Autoimmune Reactions Induced by Vaccination. <i>Journal of Autoimmunity</i> , 2001, 16, 309-318.	6.5	129
48	Population-based study of rotavirus vaccination and intussusception. <i>Pediatric Infectious Disease Journal</i> , 2001, 20, 410-416.	2.0	210
49	Vaccine risks: real, perceived and unknown. <i>Vaccine</i> , 1999, 17, S41-S46.	3.8	139
50	Vaccine adverse events: causal or coincidental?. <i>Lancet, The</i> , 1998, 351, 611-612.	13.7	157
51	Comparative Safety of Two Recombinant Hepatitis B Vaccines in Children. <i>Journal of Clinical Epidemiology</i> , 1998, 51, 503-510.	5.0	62
52	The Guillain-Barré Syndrome and the 1992-1993 and 1993-1994 Influenza Vaccines. <i>New England Journal of Medicine</i> , 1998, 339, 1797-1802.	27.0	489
53	Vaccine Safety: Current and Future Challenges. <i>Pediatric Annals</i> , 1998, 27, 445-455.	0.8	93
54	INDICATIONS FOR MEASLES-MUMPS-RUBELLA VACCINATION IN A CHILD WITH PRIOR THROMBOCYTOPENIA PURPURA. <i>Pediatric Infectious Disease Journal</i> , 1997, 16, 423-424.	2.0	17

#	ARTICLE	IF	CITATIONS
55	The vaccine adverse event reporting system (VAERS). <i>Vaccine</i> , 1994, 12, 542-550.	3.8	342
56	Outbreak of pyogenic abscesses after diphtheria and tetanus toxoids and pertussis vaccination. <i>Pediatric Infectious Disease Journal</i> , 1993, 12, 368-371.	2.0	54
57	Confounding in Studies of Adverse Reactions to Vaccines. <i>American Journal of Epidemiology</i> , 1992, 136, 121-135.	3.4	152
58	Special Methodological Issues in Pharmacoepidemiology Studies of Vaccine Safety. , 0, , 707-732.		0
59	Special Methodological Issues in Pharmacoepidemiology Studies of Vaccine Safety. , 0, , 455-485.		15